Streetbeat News

GLTO

Galecto, Inc.

https://galecto.com

Industry

Biotechnology

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Open

5.99

Mkt cap

8.2M

Volume

5.9K

High

6.26

P/E Ratio

-0.33

52-wk high

23.50

Low

5.78

Div yield

N/A

52-wk low

5.62

Galecto, Inc. has announced a 1-for-25 reverse stock split, effective at 5:00 p.m. ET on August 29. This corporate action is aimed at increasing the per-share trading price of its common stock.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 1:01 pm

Oppenheimer analyst Jay Olson maintains an Outperform rating on Galecto (NASDAQ:GLTO) but lowers the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 11:19 am

In Friday's after-market session, several healthcare stocks showed notable movements. Qilian Intl Hldg Gr (QLI) led the gainers with a 50.4% increase, while PaxMedica (PXMD) experienced the largest decline among the losers, dropping 8%. Other notable movers included Allarity Therapeutics (ALLR) and Cormedix (CRMD) with significant gains, and OncoCyte (OCX) which declined following its Q4 earnings release.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 8:31 pm

In Monday's after-market session, several health care stocks showed significant movement. OpGen, Galecto, and Kyverna Therapeutics were among the top gainers, with shares increasing by 24.0%, 9.93%, and 9.19% respectively. On the losing end, Gritstone Bio saw a significant drop of 41.7%, followed by Aclarion and Qilian Intl Hldg Gr with declines of 17.08% and 7.1%. Other notable movements included Matinas BioPharma and Ontrak with increases, and BioVie, ABVC BioPharma, and Humana with decreases.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 8:31 pm

In Wednesday's after-market session, health care stocks saw significant movements. Molina Healthcare led the gainers with a 24.2% increase, while Spruce Biosciences experienced the largest drop, declining by 75.2%. Other notable movers include Evoke Pharma, Aptorum Gr, and Galecto on the gainers' side, and Qilian Intl Hldg Gr, NuCana, and Regencell Bioscience among the losers.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 9:32 pm

In Tuesday's after-market session, several health care stocks showed significant movement. Sharps Technology and DMK Pharmaceuticals led the gainers with over 20% increases in their stock prices, while Exicure and Yield10 Bioscience were among the top losers, experiencing declines of over 6%. Notably, Arrowhead Pharma and Varex Imaging reported their Q1 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 9:31 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. SINTX Techs (SINT) saw a 75% increase, while Solid Biosciences (SLDB) dropped by 10.3%. Other notable gainers include NuCana (NCNA), CNS Pharma (CNSP), OneMedNet (ONMD), Galecto (GLTO), and Accelerate Diagnostics (AXDX). On the losing side, Spruce Biosciences (SPRB), Celularity (CELU), Assure Holdings (IONM), Petros Pharma (PTPI), and Iterum Therapeutics (ITRM) saw declines in their stock prices.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 9:31 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Karuna Therapeutics (KRTX) saw a substantial increase of 47.9%, while AlloVir (ALVR) faced a sharp decline of 57.5%. Other notable gainers include Senti Biosciences (SNTI), SenesTech (SNES), Galecto (GLTO), TC BioPharm (TCBP), and Reviva Pharmaceuticals (RVPH). Conversely, 60 Degrees (SXTP), Nanobiotix (NBTX), DMK Pharmaceuticals (DMK), Oncternal Therapeutics (ONCT), and ThermoGenesis Holdings (THMO) were among the losers.

Portfolio Pulse from Benzinga Insights

December 22, 2023 | 1:07 pm

Galecto, Inc. shares surged following the announcement of positive topline results from their Phase 2a trial of GB2064, aimed at treating myelofibrosis.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 9:59 pm

In Thursday's after-market session, several healthcare stocks experienced significant movements. NuCana, Galecto, Ensysce Biosciences, Atara Biotherapeutics, 60 Degrees, and PetVivo Holdings saw their shares rise, with increases ranging from 7.75% to 15.6%. Conversely, Oncternal Therapeutics, Altamira Therapeutics, Nuwellis, DMK Pharmaceuticals, ASLAN Pharma, and SCWorx saw their shares decline, with decreases ranging from 5.65% to 12.7%. These movements reflect changes in investor sentiment and market dynamics for these small-cap companies.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.